Silverfin false false 31/05/2025 01/06/2024 31/05/2025 S J Eccles 28/05/2021 T S Rees 28/05/2021 31 March 2026 The principal activity of the company is that of specialists medical practice services. 13426787 2025-05-31 13426787 bus:Director1 2025-05-31 13426787 bus:Director2 2025-05-31 13426787 2024-05-31 13426787 core:CurrentFinancialInstruments 2025-05-31 13426787 core:CurrentFinancialInstruments 2024-05-31 13426787 core:ShareCapital 2025-05-31 13426787 core:ShareCapital 2024-05-31 13426787 core:RetainedEarningsAccumulatedLosses 2025-05-31 13426787 core:RetainedEarningsAccumulatedLosses 2024-05-31 13426787 core:OtherResidualIntangibleAssets 2024-05-31 13426787 core:OtherResidualIntangibleAssets 2025-05-31 13426787 core:PlantMachinery 2024-05-31 13426787 core:Vehicles 2024-05-31 13426787 core:ComputerEquipment 2024-05-31 13426787 core:PlantMachinery 2025-05-31 13426787 core:Vehicles 2025-05-31 13426787 core:ComputerEquipment 2025-05-31 13426787 bus:OrdinaryShareClass1 2025-05-31 13426787 2024-06-01 2025-05-31 13426787 bus:FilletedAccounts 2024-06-01 2025-05-31 13426787 bus:SmallEntities 2024-06-01 2025-05-31 13426787 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 13426787 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 13426787 bus:Director1 2024-06-01 2025-05-31 13426787 bus:Director2 2024-06-01 2025-05-31 13426787 core:OtherResidualIntangibleAssets core:TopRangeValue 2024-06-01 2025-05-31 13426787 core:OtherResidualIntangibleAssets 2024-06-01 2025-05-31 13426787 core:PlantMachinery core:TopRangeValue 2024-06-01 2025-05-31 13426787 core:Vehicles core:TopRangeValue 2024-06-01 2025-05-31 13426787 core:ComputerEquipment core:TopRangeValue 2024-06-01 2025-05-31 13426787 2023-06-01 2024-05-31 13426787 core:PlantMachinery 2024-06-01 2025-05-31 13426787 core:Vehicles 2024-06-01 2025-05-31 13426787 core:ComputerEquipment 2024-06-01 2025-05-31 13426787 bus:OrdinaryShareClass1 2024-06-01 2025-05-31 13426787 bus:OrdinaryShareClass1 2023-06-01 2024-05-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 13426787 (England and Wales)

# SIMON ECCLES PLASTIC SURGERY LIMITED

### Unaudited Financial Statements
For the financial year ended 31 May 2025
Pages for filing with the registrar

SIMON ECCLES PLASTIC SURGERY LIMITED

## Unaudited Financial Statements

For the financial year ended 31 May 2025

Contents

SIMON ECCLES PLASTIC SURGERY LIMITED

## STATEMENT OF FINANCIAL POSITION

As at 31 May 2025
SIMON ECCLES PLASTIC SURGERY LIMITED

## STATEMENT OF FINANCIAL POSITION (continued)

As at 31 May 2025

| Note | 2025 |  | 2024
|  | £ |  | £
Fixed assets |  |  |  |
Tangible assets | 4 | 16,723 |  | 39,522
|  | 16,723 |  | 39,522
Current assets |  |  |  |
Stocks |  | 2,770 |  | 3,443
Debtors | 5 | 275,072 |  | 294,205
Cash at bank and in hand |  | 533,528 |  | 391,419
|  | 811,370 |  | 689,067
Creditors: amounts falling due within one year | 6 | ( 188,576) |  | ( 217,068)
Net current assets |  | 622,794 |  | 471,999
Total assets less current liabilities |  | 639,517 |  | 511,521
Net assets |  | 639,517 |  | 511,521
Capital and reserves |  |  |  |
Called-up share capital | 7 | 100 |  | 100
Profit and loss account |  | 639,417 |  | 511,421
Total shareholders' funds |  | 639,517 |  | 511,521

For the financial year ending 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Statement of Income and Retained Earnings has not been delivered.

The financial statements of Simon Eccles Plastic Surgery Limited (registered number: 13426787) were approved and authorised for issue by the Board of Directors. They were signed on its behalf by:

S J Eccles Director |

31 March 2026

SIMON ECCLES PLASTIC SURGERY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 May 2025
SIMON ECCLES PLASTIC SURGERY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 May 2025

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

Simon Eccles Plastic Surgery Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the company's registered office is First Floor, 5 Fleet Place, London, EC4M 7RD, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Going concern

The directors have assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

##### Turnover

Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts and settlement discounts.
Turnover is recognised when the service has been provided.

##### Employee benefits

Short term benefits
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Defined contribution schemes
The company operates a defined contribution scheme. The amount charged to the Statement of Income and Retained Earnings in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Statement of Financial Position.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.
Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.
The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

##### Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Other intangible assets | 2 years straight line

###### Other intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

##### Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery | 3 years straight line
Vehicles | 5 years straight line
Computer equipment | 3 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

##### Leases

The company as lessee
Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

##### Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Non-financial assets
At each balance sheet date, the company reviews its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss.
If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

##### Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

##### Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

##### Financial instruments

The Company only enters into basic financial instruments and transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to and from related parties and investments in non-puttable ordinary shares.

Financial assets
Basic financial assets, including trade and other debtors, and amounts due from related companies, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.
Such assets are subsequently carried at amortised cost using the effective interest method.
At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in the Statement of Income and Retained Earnings/Statement of Comprehensive Income.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities
Basic financial liabilities, including trade and other creditors and accruals, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Equity instruments
Equity instruments issued by the company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

#### 2. Employees

| 2025 |  | 2024
| Number |  | Number
Monthly average number of persons employed by the company during the year, including directors | 2 |  | 2

#### 3. Intangible assets

| Other intangible assets |  | Total
| £ |  | £
Cost |  |  |
At 01 June 2024 | 35,000 |  | 35,000
At 31 May 2025 | 35,000 |  | 35,000
Accumulated amortisation |  |  |
At 01 June 2024 | 35,000 |  | 35,000
At 31 May 2025 | 35,000 |  | 35,000
Net book value |  |  |
At 31 May 2025 | 0 |  | 0
At 31 May 2024 | 0 |  | 0

#### 4. Tangible assets

| Plant and machinery |  | Vehicles |  | Computer equipment |  | Total
| £ |  | £ |  | £ |  | £
Cost |  |  |  |  |  |  |
At 01 June 2024 | 3,540 |  | 69,990 |  | 2,157 |  | 75,687
Additions | 0 |  | 0 |  | 2,499 |  | 2,499
At 31 May 2025 | 3,540 |  | 69,990 |  | 4,656 |  | 78,186
Accumulated depreciation |  |  |  |  |  |  |
At 01 June 2024 | 1,377 |  | 33,829 |  | 959 |  | 36,165
Charge for the financial year | 1,180 |  | 23,330 |  | 788 |  | 25,298
At 31 May 2025 | 2,557 |  | 57,159 |  | 1,747 |  | 61,463
Net book value |  |  |  |  |  |  |
At 31 May 2025 | 983 |  | 12,831 |  | 2,909 |  | 16,723
At 31 May 2024 | 2,163 |  | 36,161 |  | 1,198 |  | 39,522

#### 5. Debtors

| 2025 |  | 2024
| £ |  | £
Trade debtors | 72,845 |  | 56,905
Other debtors | 202,227 |  | 237,300
| 275,072 |  | 294,205

#### 6. Creditors: amounts falling due within one year

| 2025 |  | 2024
| £ |  | £
Corporation tax | 164,541 |  | 156,203
Other taxation and social security | 204 |  | 1,361
Other creditors | 23,831 |  | 59,504
| 188,576 |  | 217,068

#### 7. Called-up share capital

| 2025 |  | 2024
| £ |  | £
Allotted, called-up and fully-paid |  |  |
100 Ordinary shares of £ 1.00 each | 100 |  | 100

#### 8. Related party transactions

During the year advances amounting to £610,095 (2024 - £383,921) were made to S J Eccles. Repayments of the loan during the year amounted to £340,054 (2024 - £40,755), dividends of £325,000 (2024: £699,000 ) were declared and interest of £4,691 (2024 - £15,255) was charged. At 31 May 2025, £10,493 (2024 - £60,761) was due from S J Eccles. The loan bears interest at 2.25% and is repayable on demand.